“…All of the studies were published between January 2010 and March 2021. In general, ten studies aimed to develop new formulation of biomaterials [ 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 ]; three studies focused in improving or characterizing current biomaterials [ 46 , 47 , 48 ]; one study investigated the effect of the biomaterials toward inflammation [ 49 ]; three studies intended to improve fabrication methods in order to produce better biomaterials [ 36 , 46 , 50 ]. The biomaterials studied in the included articles were carbomer hydrogel, micronized dermal graft tissue, crosslinked HA, HA with gelatine hydrogel, CaHA, carboxymethylcellulose (CMC), bovine collagen, micronized alloderm (Cymetra) (Lifecell Corp, Branchburg, NJ, USA), HA gel, carboxylic and hydroxylic multi-walled functionalized carbon, unequal particle sized middle viscosity and low viscosity HA, Rofilan (Laborata es Filorga, Lisbonne, Paris, France),Radiesse (Merz, Franksville, WI, USA),Restylane (Galderma Laboratories, Fort Worth, TX, USA), dextran beads in HA microsphere (MP), polyethylene glycol-diamine (PEG) microparticles, gelatine methacrylate MP, HA methacrylate, semi-IPN MP, glycol chitosan hydrogel, pluronic F127 with collagen, HA with poly(ethylene glycol) diacrylate (PEGDA) crosslinkers, silk protein based in HA suspension, resilin-like-polypeptide hydrogel, PEG30 hydrogel and polydimethylsiloxane (PDMS) with polydopamine (PDA).…”